Boothbay Fund Management LLC Has $976,000 Stock Holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Boothbay Fund Management LLC decreased its position in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 29.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 106,309 shares of the medical technology company's stock after selling 44,867 shares during the quarter. Boothbay Fund Management LLC owned about 0.07% of Alphatec worth $976,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of ATEC. PNC Financial Services Group Inc. lifted its position in shares of Alphatec by 0.4% during the 4th quarter. PNC Financial Services Group Inc. now owns 312,954 shares of the medical technology company's stock valued at $2,873,000 after acquiring an additional 1,120 shares during the last quarter. Summit Investment Advisors Inc. lifted its holdings in shares of Alphatec by 14.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 10,890 shares of the medical technology company's stock valued at $100,000 after purchasing an additional 1,342 shares during the last quarter. Rhumbline Advisers boosted its position in shares of Alphatec by 1.3% in the 4th quarter. Rhumbline Advisers now owns 139,088 shares of the medical technology company's stock valued at $1,277,000 after purchasing an additional 1,746 shares during the period. Swiss National Bank boosted its position in shares of Alphatec by 1.1% in the 4th quarter. Swiss National Bank now owns 207,200 shares of the medical technology company's stock valued at $1,902,000 after purchasing an additional 2,300 shares during the period. Finally, CIBC Private Wealth Group LLC increased its stake in Alphatec by 19.1% in the 4th quarter. CIBC Private Wealth Group LLC now owns 17,154 shares of the medical technology company's stock worth $166,000 after purchasing an additional 2,750 shares in the last quarter. Institutional investors own 66.35% of the company's stock.

Alphatec Stock Performance

Shares of ATEC traded up $0.94 during mid-day trading on Friday, hitting $12.00. The company's stock had a trading volume of 4,701,141 shares, compared to its average volume of 2,074,909. Alphatec Holdings, Inc. has a one year low of $4.88 and a one year high of $13.79. The stock's 50-day moving average is $10.46 and its two-hundred day moving average is $9.89. The firm has a market capitalization of $1.75 billion, a PE ratio of -9.38 and a beta of 1.20. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32.

Alphatec (NASDAQ:ATEC - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical technology company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.23). Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. The company had revenue of $169.18 million for the quarter, compared to the consensus estimate of $167.57 million. During the same quarter in the previous year, the firm posted ($0.34) EPS. The business's revenue for the quarter was up 22.2% compared to the same quarter last year. As a group, sell-side analysts anticipate that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Insider Activity

In other Alphatec news, CEO Patrick Miles sold 43,459 shares of Alphatec stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $11.95, for a total transaction of $519,335.05. Following the completion of the transaction, the chief executive officer now directly owns 6,065,772 shares of the company's stock, valued at approximately $72,485,975.40. This trade represents a 0.71 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Scott Lish sold 27,453 shares of the company's stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $11.49, for a total transaction of $315,434.97. Following the sale, the chief operating officer now directly owns 867,677 shares in the company, valued at $9,969,608.73. This represents a 3.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 222,113 shares of company stock worth $2,519,725. Company insiders own 22.80% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Needham & Company LLC reiterated a "buy" rating and issued a $16.00 target price on shares of Alphatec in a report on Friday. Piper Sandler reiterated an "overweight" rating and set a $15.00 price objective (up from $13.00) on shares of Alphatec in a research report on Friday. StockNews.com upgraded Alphatec from a "sell" rating to a "hold" rating in a report on Friday, February 28th. HC Wainwright reiterated a "buy" rating and set a $20.00 price target on shares of Alphatec in a report on Monday, April 14th. Finally, Barclays raised their price objective on Alphatec from $20.00 to $21.00 and gave the stock an "overweight" rating in a research report on Wednesday, January 22nd. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat.com, Alphatec presently has an average rating of "Moderate Buy" and an average price target of $17.89.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.